Is Wall Street Bullish or Bearish on Insulet Stock?

Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an progressive medical machine company. Valued at $10.1 billion by market cap, the company develops, manufactures, and sells insulin supply systems for people with insulin-dependent diabetes.

Shares of this insulin infusion systems maker have significantly underperformed the broader market over the previous 12 months. PODD has declined 56% over this time body, while the broader S&P 500 Index ($SPX) has rallied almost 18.3%. In 2026, PODD stock is down 48.8%, in contrast to the SPX’s 11.8% rise on a YTD foundation. 

More News from Barchart

Narrowing the focus, PODD’s underperformance is also obvious in contrast to the iShares U.S. Medical Devices ETF (IHI). The exchange-traded fund has declined about 11.1% over the previous 12 months. Moreover, the ETF’s 10.1% dip on a YTD foundation outshines the stock’s losses over the same time body. 

PODD underperformed as market sentiment was weighed down by industrial friction in its Type 2 diabetes phase, key adoption considerations, and intensifying competitors. While top-line growth remained stable via its Omnipod 5 system, buyers reacted sharply to lower-than-expected retention charges among new Type 2 customers during their first 90 days of therapy, forcing a reevaluation of affected person onboarding and industrial support fashions. Compounding these retention hiccups, broader macro anxiety over GLP-1 adoption dampening long-term insulin demand and aggressive stress from rival automated insulin supply suppliers dampened investor enthusiasm, offsetting management’s progress in increasing U.S. insurance coverage protection and stabilizing pricing.

On Aug. 5, PODD shares nosedived over 20% after reporting its Q2 outcomes. Its adjusted EPS of $1.66 beat Wall Street expectations of $1.44. The company’s income was $801.7 million, topping Wall Street forecasts of $786.8 million.

For the present fiscal 12 months, ending in December, analysts expect PODD’s EPS to grow 31% to $6.51 on a diluted foundation. The company’s earnings shock historical past is spectacular. It beat the consensus estimate in each of the last 4 quarters.

Among the 27 analysts masking PODD stock, the consensus is a “Moderate Buy.” That’s based mostly on 13 “Strong Buy” scores, two “Moderate Buys,” 11 “Holds,” and one “Strong Sell.”

This configuration is less bullish than a month in the past, with a “Strong Buy” ranking general, consisting 19 analysts suggesting a “Strong Buy.”

On Aug. 13, Citigroup Inc. (C) analyst Joanne Wuensch maintained a “Hold” ranking on PODD and set a price goal of $150, implying a potential upside of 3.1% from present ranges.

The imply price goal of $172.46 represents an 18.6% premium to PODD’s present price ranges. The Street-high price goal of $275 suggests an bold upside potential of 89.1%. 

On the date of publication, Neha Panjwani did not have (either immediately or not directly) positions in any of the securities talked about in this article. All info and knowledge in this article is solely for informational functions. This article was initially printed on Barchart.com